But the Supreme Court decision affirms ongoing access to the drug for now, as a three-judge panel reviews the Fifth Circuit case. At the same time, a second lawsuit could expand access to mifepristone in Washington, the District of Columbia and 16 other states. That lawsuit is moving forward, said Attorney General Ferguson on Friday.
While some media accounts described the Supreme Court’s decision as retaining “broad” or “unfettered” access to mifepristone, the drug has never been widely available. Under a restriction known as a risk evaluation and mitigation strategy, the FDA has curtailed access to the drug through a series of requirements more typically applied to medications with indisputably
→ Continue reading at Crosscut
